GlassScriptPhysician profile
Stephen Awuor
NPI 1790047736
$3,284.75
in general payments reported to CMS, 2019-2025
25 companies · $909 in 2025
The $909 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $30.43 · 2021: $206 · 2022: $443 · 2023: $870 · 2024: $661 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641 · Consulting Fee: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.90 |
| Consulting Fee | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $800.00 | 2023-2025 | Navicross |
| Abiomed | $442.25 | 2022-2024 | Impella |
| Boston Scientific Corporation | $362.27 | 2019-2024 | Emerge Push, Synergy, Rotablator Rotational Atherectomy System Console Kit |
| E.R. Squibb & Sons, L.L.C. | $243.88 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $183.07 | 2021-2023 | Supera |
| Shockwave Medical, INC | $168.17 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $159.77 | 2023-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.37 | 2022-2025 | Jardiance |
| Penumbra, INC. | $101.00 | 2022 | |
| Chiesi USA, INC. | $100.19 | 2021-2025 | Juxtapid, Kengreal |
| Actelion Pharmaceuticals US, INC. | $96.16 | 2022-2025 | Uptravi, Opsynvi, Opsumit |
| Pfizer INC. | $81.55 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $52.78 | 2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.32 | 2020-2024 | Lifevest |
| Medtronic, INC. | $48.06 | 2022-2023 | Corevalve Evolut R, In.Pact Admiral |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.94 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $40.16 | 2022-2024 | |
| Amgen INC. | $39.40 | 2023 | Repatha |
| Novo Nordisk INC | $34.63 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $21.74 | 2025 | |
| Cardiovascular Systems INC. | $21.09 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.60 | 2024 | |
| Inspire Medical Systems, INC. | $17.92 | 2025 | Inspire |
| Inari Medical, INC. | $14.87 | 2020 | |
| Angiodynamics, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Awuor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.